Skip to main content

Table 8 Clinical features of different antibody combinations in EBV-positive patients (age ≥8 months)

From: The impact of serological features in Chinese children with primary or past Epstein–Barr virus infections

Clinical features

A (n = 17)

B (n = 8)

C (n = 13)

D (n = 112)

E (n = 121)

Length of stay (days)

10.5 ± 2.9*

10.4 ± 4.9

9.0 ± 4.5

8.0 ± 2.9*

9.1 ± 4.0

Fever

17 (100.0%)

8 (100.0%)

12 (92.3%)

100 (89.3%)

106 (87.6%)

Cough

9 (52.9%)

8 (100.0%)

12 (92.3%)

79 (70.5%)

90 (74.4%)

Rash

4 (23.5%)

4 (50.0%)

0 (0.0%)

23 (20.5%)

19 (15.7%)

Lymphadenopathy

11 (64.7%)**

6 (75.0%)

5 (38.5%)

41 (36.6%)

35 (28.9%)*

Pharyngitis

16 (94.1%)

7 (87.5%)

10 (76.9%)

89 (79.5%)

87 (71.9%)

Palatal petechiae

9 (52.9%)**

2 (25.0%)

5 (38.5%)

20 (17.9%)*

24 (19.8%)

Abnormal chest X ray

8/9 (88.9%)

2/2 (100.0%)

3/5 (60.0%)

50/57 (87.7%)

53/65 (81.5%)

Bronchitis (X ray)

3/9 (33.3%)

1/2 (50.0%)

2/5 (40.0%)

32/57 (56.1%)

25/65 (38.5%)

Pneumonia (X ray)

5/9 (55.6%)

1/2 (50.0%)

1/5 (20.0%)

18/57 (31.6%)

28/65 (43.1%)

Hepatomegaly

5 (29.4%)

2 (25.0%)

3 (23.1%)

7 (6.3%)

11 (9.1%)

Splenomegaly

4 (23.5%)

0 (0.0%)

1 (7.7%)

7 (6.3%)

5 (4.1%)

ALC >10%

12/15 (80.0%)**

0/6 (0.0%)*

4/8 (50.0%)

14/66 (21.2%)*

18/77 (23.4%)*

Elevated ESR

8/14 (57.1%)

5/6 (83.3%)

2/10 (20.0%)

43/81 (53.1%)

31/66 (47.0%)

Elevated CRP

4/13 (30.8%)

5/6 (83.3%)

5/9 (55.6%)

42/83 (50.6%)

43/76 (56.6%)

ALF

9/13 (69.2%)

1/4 (25.0%)

2/6 (33.3%)

9/36 (25.0%)

15/38 (39.5%)

  1. A: patients with the antibody combination of [VCA-IgM+, VCA-IgG– and EBNA-IgG–]. B: patients with the antibody combination of [VCA-IgM+, VCA-IgG+ and EBNA-IgG+]. C: patients with the antibody combination of [VCA-IgM–, VCA-IgG+ and EBNA-IgG–]. D: patients with the antibody combination of [VCA-IgM–, VCA-IgG+ and EBNA-IgG+]. E: patients with the antibody combination of [VCA-IgM–, VCA-IgG– and EBNA-IgG–]. ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; ALC, atypical lymphocytes; ALF, abnormal liver function (alanine aminotransferase or aspartate aminotransferase levels >46 U/L). P < 0.05 between * and **.